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Skeletal muscle mass and quality, which is determined by day-to-day changes in muscle 
protein synthesis (MPS) and muscle protein breakdown rates (MPB), are important determinants 
of physical performance and metabolic health across all age groups. As such, identifying 
nutritional and exercise strategies that more robustly stimulate MPS and inhibit MPB after each 
meal are important to optimize skeletal muscle mass and health. The leucine content of a meal is 
believed to be an important anabolic characteristic of a meal. Specifically, leucine is a potent 
amino acid that serves both as an anabolic signaling molecule and substrate to potentiate MPS. 
Beyond single amino acids, food proteins also contain dipeptides. Little is known, however, 
about the anabolic and catabolic effects of dipeptides, whose uptake rates have been shown to be 
faster than corresponding free amino acid. As such, uncovering how dipeptides impact muscle 
protein turnover is warranted to develop more anabolic nutritional strategies. The study within 
this thesis aimed to determine the effect of dipeptide (i.e., leucine-leucine; DILEU) ingestion on 
changes in MPS and MPB rates when compared to leucine (LEU) in single form. Ten young men 
completed a double-blind, randomized crossover study. Participants were randomized to ingest 
either 2.00g of LEU or 2.47g of DILEU mixed in 150mL of water. After an overnight fast, 
participants received a primed constant infusion of L-[ring-13C6]- and [
15N]-phenylalanine to 
measure MPS and MPB rates. Plasma insulin, glucose, leucine and dileucine concentrations were 
also measured.  Results from this study demonstrated that DILEU stimulates MPS to a greater 
extent than LEU. There was no difference in MPB rates between conditions. Plasma insulin, 
glucose, leucine, and dileucine concentrations did not differ between conditions. These data 
suggest that DILEU may be used in food fortification or clinical feeding formulas to enhance the 
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CHAPTER 1: INTRODUCTION 
 Skeletal muscle is a vital tissue of the human body that contributes to locomotion, 
physical performance, and several aspects of metabolic health (1–4). Strategies to maximize 
skeletal muscle mass and quality are important to maintain (or improve) physical function and 
muscle metabolic health with age. Skeletal muscle mass and quality are determined by day-to-
day changes in muscle protein synthesis (MPS) and breakdown (MPB) rates to each individual 
meal. To this end, strategies have been developed to impact net muscle protein balance 
(NPB=MPS – MPB) and enhance muscle protein turnover across all age groups (5,6). Essential 
amino acids (EAAs) have been identified as robust stimulators of MPS (7) and have been used—
in conjunction with other interventions such as resistance exercise (8,9)— to improve muscle 
health. 
 Of the nine EAAs, leucine has been identified as the EAA with the most anabolic 
potential (10–12). Animal and cell culture studies have demonstrated that leucine directly targets 
the mammalian target of rapamycin (13–15) and its downstream targets (15–17)—this pathway 
is responsible for the creation of new muscle proteins. Moreover, leucine has been indicated to 
suppress MPB (18,19), further contributing to its anabolic potential. In human studies, leucine 
ingestion has led to robust increases in MPS (20–22) and has been utilized as a pharmaconutrient 
to combat metabolic disease (1,23). 
 Dipeptides are organic compounds composed of two amino acids—can either be the same 
or different amino acids— that are subsequently dehydrated and bound together. These amino 
acids can either be produced synthetically —via chemical synthesis, chemoenzymatic synthesis, 
or enzymatic synthesis— or as a result of the breakdown of larger proteins in the gastrointestinal 
system (24,25). Studies in patients with gastrointestinal disease suggest that dipeptides can be 
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absorbed into peripheral circulation through a different set of pathways that are independent of 
free amino acids (26–29). Indeed, data collected in human and animal models suggest that 
dipeptides are absorbed at a faster rate than free amino acids (30–32)—meaning skeletal muscle 
can utilize these compounds more quickly for skeletal muscle protein remodeling. To this end, 
no study has yet to investigate how dipeptides directly impact MPS and MPB postprandially. 
 
Specific Objectives and Hypothesis 
The objective of this thesis was to determine how the ingestion of the dipeptide dileucine 
impacts MPS and MPB— when compared to the ingestion of leucine alone— in young healthy 
adult males. A secondary objective of this thesis was to determine the effect of these amino acids 
on postprandial plasma insulin, glucose, leucine, and dileucine concentrations. In a double-blind, 
randomized crossover design investigation, individuals completed two primed-constant, stable 
isotope infusion trials. For both trials, muscle fractional synthetic rates (FSR) and fractional 
breakdown rates (FBR) were measured as these are the most direct measurements of muscle 
protein turnover. Additionally, blood plasma glucose, insulin, leucine, and dileucine 
concentrations were measured. 
We hypothesized that dileucine ingestion would augment MPS and decrease MPB when 
compared to leucine. Additionally, because amino acids have capacities as hormone 
secretagogues, we hypothesized increases in plasma insulin concentrations for both dileucine and 
leucine ingestion—but no increase in glucose concentrations. The subsequent chapters will 
summarize the current state of the literature, the methodology, results, and overall discussion and 
conclusions of this investigation.
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CHAPTER 2: LITERATURE REVIEW 
This chapter will cover a discussion of the role of skeletal muscle in human metabolism, how 
fluctuations in muscle protein turnover (i.e., changes in synthesis and breakdown rates) impact 
health, and the importance of targeted dietary interventions in the preservation of skeletal muscle 
tissue. Current stable isotope amino acid infusion methodologies used to measure MPS and MPB 
rates will also be discussed. A section of this review will discuss the anabolic potential of the amino 
acid leucine and its purposed impact on stimulating changes in MPS and MPB rates. Lastly, 
dipeptide digestion and absorption will be discussed.  These topics have been chosen to underline the 
potential role of dipeptides in human skeletal muscle metabolism and its implication on measures of 
MPS and MPB rates in healthy adults.  
2.1 Importance of Skeletal Muscle for Health 
Skeletal muscle quality is an important determinant of exercise performance and overall 
health. Decades of research has shown how the preservation of skeletal muscle mass, especially 
into advanced age, maintains physiological and functional capacity. Skeletal muscle is an organ 
that plays multiple roles that go beyond human movement. These roles include: 1) regulation of 
blood glucose and nutrient intake; 2) contributing to the regulation of the post-prandial insulin 
response; and 3) serving as an endocrine organ (33). Losses in muscle strength and muscle mass 
are more likely into advanced age (6,34). As such, identifying strategies to more effectively 
preserve and optimize skeletal muscle quantity and quality across the lifespan present high 
relevance to researchers and clinicians.  
Human skeletal muscle is a dynamic tissue that constantly undergoes remodeling 
processes. These processes occur both under acute and long-term situations and can have a 
considerable impact on an individual’s muscle health. Muscle protein turnover is a combination 
of two distinct processes—MPS and MPB rates. MPS is defined as the process by which amino 
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acids are arranged to make proteins based on the mRNA template. MPB is defined as the process 
of hydrolyzing the functional native protein molecule to its constituent amino acids and 
prosthetic groups and the subsequent catabolism of the component amino acids (35). A net 
positive change typically occurs when synthesis rates exceed those of breakdown rates. 
Conversely, a net negative change occurs when breakdown rates exceed those of protein 
synthesis (36). Maintaining a net negative protein balance over an extended period of time can 
conversely lead to skeletal muscle loss (5).  
One of the most robust stimulators of MPS rates is the ingestion of protein—more 
specifically EAAs. EAAs enhance MPS through anabolic signaling pathways leading to 
transcription, translation initiation, and elongation (37). Consuming EAAs becomes increasingly 
more important into advanced age—as it has been shown that EAAs are primarily responsible for 
muscle protein anabolism, primarily by stimulating MPS (7). Considering that human MPS is 
regulated by extracellular amino acids availability in circulation in healthy adults (38), ensuring 
adequate quantity and quality of dietary proteins are consumed is key to ensuring a positive net 
muscle protein balance is achieved. This positive net balance can be further enhanced by 
coupling protein intake with resistance exercise—resulting in additional increases of MPS (9).  
2.2 Measurement of Muscle Protein Synthesis and Breakdown Rates in vivo in Humans 
Considering the dynamic nature of skeletal muscle protein turnover, methods have been 
devised to directly measure protein synthesis and breakdown rates in vivo in humans —allowing 
researchers the ability to define the impact of anabolic stimuli (i.e., protein ingestion and 
exercise) on skeletal muscle protein metabolism. Of these methods, stable isotope amino acid 
tracers have been widely utilized to measure skeletal muscle protein turnover because: 1) tracers 
have chemically identical properties to amino acids in human circulation; 2) pose little to no 
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harm to participants; 3) can be readily used in cross-over designs, and; 4) methods and models 
have been developed to reliably measure protein metabolic kinetics in both normal and 
pathophysiological states (36). There are various methods available to researchers to increase 
amino acid tracer enrichment, normally expressed as tracer to tracee ratio, such as the primed 
constant infusion method, flooding dose method, etc. Of these methods, the primed constant 
infusion method is the most widely used—due in part to its straightforward modeling and the 
universal understanding of the method across the field of muscle metabolism. 
 The primed constant tracer infusion technique requires the intravenous infusion of a 
stable isotope amino acid into the precursor pool (i.e. blood and intracellular pool) and 
measuring the rate of incorporation of the tracer into the product pool (i.e. skeletal muscle). Over 
the time course of the infusion, the rate of incorporation increases, and this increase is divided by 
the average precursor pool. The goal of the precursor-product method is to determine FSR —the 
fraction of the pool of protein being measured that turns over in a given period of time. When 
this variable is multiplied by the total protein pool, an absolute muscle synthetic rate is obtained 
(35). The total protein pool is usually based on estimates of total leg mass in relation to the 
estimated amino acid concentration of the infused amino acid tracer.  
Measurement of Muscle Protein Breakdown in vivo in Humans 
 The measurement of MPB has not been as well understood as that of MPS—primarily 
due to the difficultly of modeling the measurement in humans. The lack of concurrent 
measurements of MPB in most studies is due to several factors, including: 1) MPS is believed to 
have a more substantial impact on the net protein balance of muscle than MPB in healthy adults; 
and 2) methods for modeling MPS are easier to do than MPB under non-steady state tracer 
conditions, such as after ingesting protein (39,40). Regardless of the challenges of modeling 
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MPB, it is imperative to measure MPB because this allows for a more complete understanding of 
the metabolic processes that take place after a catabolic/anabolic stimulus. More importantly, the 
measurement of MPB provides a full perspective of the effects a proposed intervention has on 
regulating skeletal muscle metabolism. 
Of the available methods to investigators, the most widely used is the arteriovenous (A-
V) balance technique. The A-V balance technique allows for the measurement of protein 
turnover across a site (e.g. forearm or leg) by measuring the inward and outward transport of 
amino acids. This method is reliant on the presence of steady state rates of blood flow around the 
target site and steady state rates of labelled and unlabeled amino acids and hormones (41). With 
that said, this method also presents an increased risk to participants as it requires the insertion of 
an arterial catheter (42)—thus requiring the presence of highly trained medical personnel. Also, 
this method only provides reliable rates of protein turnover in the limb of interest, meaning that 
reported rates are not necessarily representative of full body protein turnover rates. All told, this 
model should be used sparingly, and only after proper precautions are taken to ensure participant 
safety. 
An indirect and non-invasive method of indirectly measuring MPB is the 3-
Methylhistidine (3 MeH) method. The rate of excretion of 3-MeH—an amino acid formed by the 
methylation of histidine residues of myofibrillar actin and myosin—is measured by collecting all 
the excreted urine of a participant and measuring MPB using a standard equation. 3 MeH is 
targeted for this measurement because it is primarily present in skeletal muscle at a constant 
concentration, is released via the process of MPB and is not reutilized by the muscle or 
metabolized by the body, and undergoes rapid and measurable excretion in urine (35). However, 
this method can be unreliable if not done with tracer dilution, measurements of muscle blood 
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flow and muscle microvascular blood flow, and ceasing of meat consumption leading up to and 
during the experiment. Investigators must also consider the variable rates of 3 MeH excretion by 
other body tissues that can impact the estimation of MPB (35,40). 
A third method was developed by Zhang et al. (43) to directly measure MPB in vivo, 
addressing the shortcomings of the previously mentioned methods as well as expanding on the 
established direct tracer incorporation method. The “tracer dilution method” involves infusing a 
stable isotope until isotopic equilibrium is achieved in the two precursor pools (i.e. arterial and 
muscle-bound pools). Afterwards, the tracer infusion is terminated and the rate of decay in the 
precursor pools, as well as the dilution of the tracer in the product pool (i.e. muscle intracellular 
free amino acid pool (IC) pool) is observed. To validate this method, rates of MPB were 
compared to rates achieved via the A-V balance method in six dogs. FBR using the tracer 
dilution method were similar (0.17 ± 0.02 %/h) to those achieved from the A-V balance method 
(0.14 ± 0.02 %/h). Moreover, net protein balance —calculated as FSR - FBR— were similar 
between the two methods (Tracer release = -0.06 ± 0.01 %/h; A-V balance = -0.04 ± 0.01 %/h). 
These results suggest that the tracer release method is a feasible way of measuring MPB. Since 
this method was validated, other research teams have used this methodology with presumably 
reliable results (44,45). 
To successfully calculate MPB using the tracer release method, specific assumptions 
must be met. Assumptions for this method include: 1) The only source of amino acids in the 
intracellular space are from inward transport of blood & release from bound protein—meaning 
de novo synthesis of proteins cannot occur; 2) The only source of labeled amino acids in the 
intracellular space is from the inward transport of amino acids being studied; 3) the IC pool size 
is constant over time; 4) Inward transport and protein breakdown are constant over time; 5) the 
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rate at which amino acids are lost from the IC pool is constant; 6) There is no delay between the 
release from bound amino acids to its appearance in the IC pool; and 7) the IC pool acts as a 
single pool (35). Nonetheless, the tracer dilution method has multiple advantages over the A-V 
balance and 3 MeH protocols. Namely, the tracer release method can be incorporated into 
protocols measuring MPS using stable isotope methods by adding a second tracer. No additional 
muscle or blood sampling is required for this method, and sample processing for this method is 
identical to that of the MPS method. This eliminates the need for the more invasive techniques 
utilized in the other protocols and places participants under no further risk than those 
encountered in the standard stable isotope infusion protocol. All told, the tracer dilution method 
is a more feasible method for investigators lacking access to highly trained medical staff while 
still obtaining reliable data. 
2.3 Leucine as an Anabolic Trigger 
Amino acids are the building blocks of proteins and have many critical roles in human 
metabolism—some of which include serving as potent hormone secretagogues and stimulating 
the secretion of insulin, glucagon, cortisol, insulin-like growth factor 1, and growth hormone 
(23). Amino acids can be categorized into two groups: non-essential and essential. Non-essential 
amino acids are subject to de novo synthesis, meaning that the body can synthesize these amino 
acids. On the other hand, EAAs cannot be synthesized and thus need to be derived from dietary 
protein sources. Of these amino acids, leucine has been demonstrated to have a significant role in 
human metabolism due to its ability to stimulate endogenous insulin release, inhibit MPB, and 
stimulate MPS directly by acting as an anabolic signaling molecule in both healthy and diseased 
populations (23). To highlight the potency of leucine as an anabolic trigger, leucine has been 
used as a pharmaconutrient to prevent and treat sarcopenia (1,23). 
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Impact of Leucine on Protein Translation 
 Leucine has been the focus of numerous investigations dating back to the 1970s. One of 
the original studies to investigate the impact of leucine on skeletal muscle protein metabolism 
was completed by Buse and Reid (10). Researchers isolated rat hemidiaphragm with leucine and 
demonstrated that the amino acid stimulates the incorporation of amino acids into muscle 
protein. When compared to a mixture of branched chain amino acids (BCAA), leucine still 
potentiated a higher incorporation of amino acids. In 1978, Li and Jefferson (46) reported that 
leucine stimulated MPS of rat hindlimb as much as a mixture of BCAAs. Moreover, isolation of 
food deprived rat leg muscle supplemented with leucine increased protein synthesis rates 
compared to controls (47). 
 These early papers (10,46) were also some of the first investigations to suggest that 
leucine has an impact of the initiation phase of protein translation. Over time, multiple 
investigation would highlight leucine’s impact on specific downstream proteins in the protein 
synthetic machinery. Burnett et al. (48) reported oral leucine ingestion increased phosphorylation 
of ribosomal protein S6 kinase beta-1 (p70S6K), a downstream target of mammalian target of 
rapamycin (mTOR) complex 1. Leucine has also been demonstrated to have a direct impact on 
other proteins in the mTOR signaling pathway (15). Growing rats were fed either 0.27g of 
leucine, carbohydrate and leucine, or were unfed (control). The conditions containing leucine 
presented similar increases in MPS. Immunoblotting analysis demonstrated that 4E-BP1•elF4E 
complex formation —this complex is a limiting factor in mRNA translation— was inhibited. 
Moreover, elF4G-elF4E complex formation was enhanced, resulting in elF4F complex formation 
and increased mRNA initiation/translation (15). 
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 Anthony et al. (49) also elucidated the impact of the mTOR signaling pathway on 
translation initiation and MPS. Food deprived rats were allotted to one of four conditions: 1) no 
feeding (control); 2) control plus leucine administrated at 1.35g/kg bodyweight; 3) control plus 
injection of rapamycin—a potent inhibitor of the mTOR signaling pathway; or 4) rapamycin 
injection plus administration of 1.35g/kg leucine. Rats administered leucine had significantly 
higher rates of 4E-BP1 and p70S6K phosphorylation, as well as higher protein synthesis rates 
compared to rats in the rapamycin only group. Later investigations would demonstrate that 
leucine stimulates MPS independent of mTOR activity by increasing elF4G phosphorylation, 
leading to a higher formation of the elF4E•elF4G complex (50). Similarly, Crozier et al. (51) 
demonstrated rats supplemented with leucine had increased elF4G phosphorylation and increased 
MPS rates. Atherton et al. (13) investigated the anabolic signaling activity induced by amino 
acids in cell cultured Murine C2C12 myocytes. Amino acids were injected into the cells at a 
concentration of 2 mM for 30 min and probed for signaling proteins via immunoblotting. 
Investigators determined that leucine stimulated a 3-fold increase in the phosphorylation of 
p70S6K1 and RPS6. Moreover, they also demonstrated that leucine is unique in its capacity to 
stimulate mTOR complex 1 and 4E-BP1 phosphorylation—suggesting that leucine is the most 
potent anabolic signaling protein in skeletal muscle cells.  
Altogether, the data from the aforementioned studies suggest that leucine is a potent 
anabolic stimulator and can have an impact on MPS with or without directly stimulating the 
mTOR signaling pathway. While these results are consistent across various study designs, it 
must be noted that the methodologies utilized in these cell and animal models vary considerably. 
More importantly, these data must be considered within their contexts. The investigations in the 
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proceeding section expand on these findings and attempt to elucidate leucine’s anabolic potential 
in human models.  
Leucine as an Inhibitor of Proteolysis 
 In addition to stimulating increases and protein synthesis, cell and animal models suggest 
that leucine may play a role in inhibiting protein breakdown as well (52). One such study reports 
that leucine inhibits autophagy and lysosome-dependent proteolysis in a dose-dependent manner 
(53). Mouse C2C12 myotubes were starved of either leucine or all amino acids for up to 21hrs. 
Separate conditions to assess whether leucine impacted protein breakdown in a dose-dependent 
were also conducted. Leucine starvation accounted for 30-40% of total protein breakdown as 
measured by L-[35S]Met release. Moreover, leucine concentrations below average physiological 
plasma concentrations demonstrated a dose-dependent response—lower concentration of leucine 
resulted in higher rates of protein breakdown. Interestingly, investigators report that protein 
breakdown is not impacted by the mTOR signaling pathway or the amount of p70S6K 
phosphorylation (53).  
 A separate investigation reported skeletal muscle protein degradation—measured via NT-
methylhistidine release—was shown to be suppressed in rats orally fed leucine. After an 18hr 
starvation period, rats refed with a leucine diet had similar reductions in protein degradation 
when compared to rats fed a 20% casein diet, amino acid mixture, and an EAA diet. A separate 
experiment in this investigation demonstrated that oral administration of leucine alone 
(0.135g/100g BW) resulted in a decreased rate of protein degradation and increase appearance of 
serum leucine concentration (18).  
 Similar findings demonstrating proteolysis inhibition were obtained when studying chick 
skeletal muscle. Researchers incubated chick myotubes with leucine at different doses (0.2, 0.4, 
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or 1mM) for 2 or 6 hrs and measured the concentration of NT-methylhistidine in the incubation 
medium. In addition, a second experiment was conducted in which chicks were starved for 24hrs 
and then fed 225mg/100g of leucine. Chicks were sacrificed after 2hrs—muscle was obtained for 
RNA isolation and PCR analysis while blood was obtained for the measurement of NT-
methylhistidine. Leucine suppressed myofibrillar proteolysis both in chick myotubes (in a dose 
dependent manner) and in live chicks. Leucine was also reported to inhibit the PI3K and PKC 
pathways—both of which are responsible for preventing ubiquitin and proteasome C2 subunit 
mRNA expression and hence decrease protein degradation (19).  
 More recently, the potential of the leucine metabolite β-hydroxy-β-methylbutyrate 
(HMB) to inhibit proteolysis was investigated in healthy young men. Aside from stimulating 
MPS to a similar degree as leucine, HMB reduced leg proteolysis—as measured by the A-V 
balance method—by 57% from baseline. Interestingly, results showed no changes in the 
abundance of proteins associated with proteolytic activity (Calpain 1 and Caspase 3) (14). To 
date, few studies have measured MPB responses to leucine ingestion in vivo in humans—
leucine’s proposed capacity to inhibit proteolysis is founded on animal and cell modeling. 
Notably, it is currently unclear how leucine alone impacts human skeletal MPB in vivo.  
In vivo Human Studies Investigating Leucine 
 In vivo human studies eliciting the effects of leucine have been conducted in the past 
thirty years, providing scientists with insight into the role of leucine in human metabolism. 
Churchward-Venne et al. (17) examined the role of leucine on regulation of myofibrillar MPS in 
young adult males. Twenty-four males completed an acute bout of unilateral exercise before 
consuming either 1) 25g of whey protein; 2) 6.25g whey protein with added leucine to match the 
total leucine of the 25g whey condition, or: 3) 6.25g whey protein with added EAAs (except 
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leucine) to match the total EAA content of the 25g whey condition. The leucine condition had a 
similar MPS rate to the whey protein condition at 1-3hr post meal ingestion but was unable to 
sustain this increase in MPS from 3-5hrs. Additionally, phosphorylation of p70S6K was 
associated with leucine ingestion. 
 Regarding the bolus of leucine necessary to maximally stimulate an anabolic response, 
Glynn et al. (16) reported that 1.8g was sufficient to stimulate MPS when part of a EAA mixture. 
Investigators had non-exercise trained young adults consume 10g of EAA containing either: 1) 
1.8g leucine—a dose typically found in high quality protein sources, or;  2) 3.5g of leucine. MPS 
rates were not different between conditions. A separate investigation providing 3.42g of leucine 
reported a 110% increase in MPS rates over a 2.5hr post prandial period. Leucine also increased 
the phosphorylation of p70S6K and AKTSer473 (14). Another investigation reported that an EAA 
mixture containing 2.79g of leucine was able to stimulate increases in mixed MPS rates in both 
young and elderly adults—suggesting that leucine, when combined with the other EAAs, is able 
to stimulate an anabolic response in both age groups (54). That said, other studies have reported 
that leucine is unable to positively impact MPS in older adults (22,55).  
 Despite the promising literature suggesting that leucine is the primary amino acid 
responsible for stimulating MPS, other studies have suggested this is not the case. Van Vilet et 
al. (56) reported that a whole protein source, and not leucine, increased phosphorylation of 
mTORSer2448 and p70S6K—as well as increased MPS in the presence of an hyperinsulinemic 
euglycemic clamp. Twenty-eight sedentary postmenopausal women between 50-65yr were 
administered either 0.45g whey protein per kg fat free mass (FFM) (20.7g total, 2.4g leucine) or 
0.0513g leucine per kg FFM (2.4g total) in small bolus every 20mins across a 3hr time span. 
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While these data are consistent with studies looking at aging populations (22,55), this study is 
not consistent with studies providing a bolus dose of orally ingested protein (14,17).  
In vivo human research studies that utilize leucine lack methodological consistency. Such 
methods include using small boluses of leucine over an extended period of time (20,22,56–58) 
and using a single bolus of leucine (14,16,17,21). These studies have administered leucine in 
conjunction with carbohydrates and carbohydrates/EAA beverages—attempting to establish 
leucine’s role as part of a mixed meal intervention. To date, however, only one investigation has 
provided leucine in isolation during a stable isotope infusion (14)—suggesting a deficiency in 
the current body of literature. 
2.4 Mechanism and Potential Anabolic Role of Dipeptides  
Dipeptides are organic compounds composed of two amino acids—can either be the same 
or different amino acids— that are subsequently dehydrated and bound together. These amino 
acids can either be produced synthetically —via chemical synthesis, chemoenzymatic synthesis, 
or enzymatic synthesis— or as a result of the breakdown of larger proteins in the gastrointestinal 
system (24,25). Interestingly, dipeptides have been demonstrated to have a variety of uses 
commercially, which include uses as artificial sweeteners, treatment options for hypertension, 
and use as nutritional supplements (24). Animal dietary protein is one of the primary sources of 
encrypted dipeptides. Specific sources include dairy milk, cheese, meat, eggs, & various fish 
species among others (59). Dipeptides can also be derived from vegetable sources—wheat, rice, 
and soy are specific examples. In all, a total of 400 distinct dipeptides can be derived from the 20 




Amino acids and dipeptides are primarily digested in the small intestine via a 
combination of exopeptidases and endopeptidases. Regarding dipeptides, leucine aminopeptidase 
and dipeptidyl aminopeptidase are secreted from active sites of enterocytes in the brush border of 
the jejunum. These enzymes act in situ and activate when the enterocytes contact the protein 
contained within the intestinal chyme. From this point, dipeptides are broken down into their 
constituent amino acids by dipeptidases located in the endothelial cells. The products of the 
breakdown of dipeptides are then transported to the enterocytes via secondary active transport. 
This active transport is mediated by the electrochemical gradient produced by the active 
pumping of sodium & hydrogen ions into the brush border—the hydrogen-dependent co-porter 
has been identified as being specific for peptide absorption. Once transported into the cell, 
dipeptides are hydrolyzed by intracellular dipeptidases and transported out of the cell and 
subsequently introduced into the blood stream for utilization in tissue (61,62). 
Absorption Mechanisms of Dipeptides 
One of the original investigations done to understand the intestinal transport of dipeptides 
was conducted by Adibi et al. (63). There primary objective was to determine the role and 
relative importance of hydrolysis by intraluminal and membrane bound enzymes and intact 
absorption on the disappearance of dipeptides in the intestine. To accomplish this, investigators 
perfused a 30cm segment of either the duodenum, jejunum, or ileum with test solutions 
containing either glycylglycine, free glycine, glycylleucine, or equimolar amounts of free glycine 
and free leucine. Four 15-min collection of intestinal aspirates were obtained for the 
quantification of free amino acids and dipeptides, as well as blood plasma. Results demonstrated 
that dipeptide disappearance in the gut lumen is accomplished by intact absorption and not 
hydrolysis. Moreover, intracellular hydrolysis of dipeptides was shown to be greater in the ileum 
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than in the jejunum while the absorption rates of these two dipeptides were similar at these sites. 
Most importantly, these data showed that the absorption of bound amino acids (e.g. the 
constituent amino acids of the dipeptides) were absorbed at a faster rate than free amino acids 
(63). 
To expand on this idea of dipeptide absorption rates, Adibi & Soleimanpour (64) 
performed an investigation to determine whether dipeptide absorption in the human jejunum is 
mediated by a carrier-mediated transport mechanism. To test this idea, participants were infused 
with test solutions containing different concentrations of glyclglycine, glycylleucine, glycine, 
leucine, glycylleucine, or glycylleucine with an equimolar mixture of free glycine and leucine. 
Amino acids were perfused through a 15-cm segment of the jejunum, with intestinal aspirate 
collected during three 15-min collection periods for the measurement of amino acid and 
dipeptide concentrations. Transport kinetics of the studied dipeptides were greater than those of 
free amino acids—characterized by the higher digestive enzyme activity rates. Dipeptides also 
presented lower affinity for the same membrane transport sites as those of amino acids. 
Altogether, these data suggest that a transport carrier mediates the absorption of dipeptides not 
shared with free neutral amino acids (64). 
Gallo-Torres et al (30) measured the gastrointestinal absorption of intact cyclo(L-
leucylglycine) dipeptides in rats using in vivo and in vitro methods. Their investigation 
demonstrated that the dipeptides appeared in the small intestine in the first five minutes after 
administration. Absorption occurred within the first ten minutes of administration—with 98% of 
dipeptides being displaced from the stomach to the small intestine within 15mins. Interestingly, 
the investigators discovered that the dipeptides moved passively through the gastrointestinal 
system and enter the portal blood circulation intact.  
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 Scientist elucidated the specific mechanism involved in dipeptide digestion and 
absorption by studying patients with gastrointestinal absorption diseases. Patients with 
Cystinuria—characterized by insufficient intestinal transport of cystine and other amino acids—
and Hartnup where studied for these investigations. In Cystinuria and Hartnup disease, 
absorption of certain amino acid is lacking or is reduced by the malfunction of the intestinal 
transporters in both diseases (26–28). Cystinuria patients received free lysine and leucine or both 
amino acids as a dipeptide (leucyl-lysine) via perfusion of the jejunum. Absorption of lysine was 
substantially reduced when presented in the free form. However, rates of lysine absorption were 
not different from healthy controls when it was presented in the dipeptide form (29). Similar 
findings were replicated when these same disease patients were perfused with free arginine and 
L-arginyl-L-aspartate (28). In vivo absorption rates of perfused amino acids via dipeptides were 
also similar in Hartnup patients (27).  
 Numerous investigations on the substrate specificity of peptide transporter 1 (PEPT1) 
have shown a unique affinity of this transporter for most of the dipeptide substrates—however 
there is a considerable difference in uptake when factoring in a dipeptide’s characteristics. 
Peptides taken up by PEPT1 are subjected to hydrolysis by a variety of cytosolic peptidases, 
which cleave substrates intracellularly and release amino acids to the basolateral and apical 
membrane (60). A recent investigation tried to elicit if dipeptides appeared in human plasma 
postprandially after consuming a whole food meal (32). This trial had volunteers randomly 
consume 125g of rice (control), 125g of rice with 100g or chicken breast, or 125g of rice with 
200g of chicken breast. The kinetics of plasma changes of select dipeptides were derived via 
liquid chromatography–tandem mass spectrometry (LC-MS/MS) and demonstrated postprandial 
changes in a wide spectrum of dipeptides (i.e. size, charge, etc.). These changes were seen in a 
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dose dependent manner, with higher consumption of protein resulting in higher concentrations of 
amino acids in plasma. Of note, the investigators found that the substrates that appeared in 
plasma did not match the know substrate specificity of PEPT1. Additionally, their findings 
suggested that dipeptides are common in plasma circulation —their abundance is mediated by 
the dietary sources of protein consumed (32).  
 A separate investigation quantified the rates of hydrolysis and transport out of the 
basolateral membrane using Caco-2 transwell cell culture, mice models lacking the PEPT1 
transporter, and in vitro investigations using human intestinal cells models (31). Linear 
regression analysis revealed a positive correlation (R2 = 0.83) between apical disappearance and 
basolateral appearance in control and PEPT1 knockout Caco-2 cells in transwell cell culture—
dipeptides with increased resistance to hydrolysis had higher rates of basolateral appearance and 
vice versa. Dipeptides that had a higher luminal disappearance also had higher rates of 
hydrolysis and low basolateral appearance. Peptides that had a higher PEPT1 dependency where 
characterized to have low luminal disappearance and high rates of intact appearance in the 
basolateral membrane. The sensitivity of peptides to hydrolysis at the brush border membrane or 
within epithelial cells was determined to be structure dependent. Peptides possessing higher 
intrinsic resistance to hydrolysis were shown to have higher reliance on PEPT1 (main 
determinant of appearance in peripheral blood circulation) (31).   
 There is no clear indication of the impact of dipeptides on the rates of MPS and MPB in 
humans—all the literature related to dipeptides pertains to its absorption characteristics. To date, 
no investigation has gone so far as to elucidate the effect of dipeptide’s faster absorption rates on 
muscle protein metabolism. Determining the extent of dipeptide’s anabolic potential could prove 
valuable to scientist attempting to find new ways of preserving and maximizing skeletal muscle. 
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Dileucine —structurally composed of two leucine amino acids—is a dipeptide of interest 
because of its potential to positively impact human skeletal muscle metabolism. As mentioned 
above, leucine has been shown to have a positive impact on both MPS and MPB. Pilot work has 
suggested that the ingesting of dileucine results in an elevation of plasma dileucine 
concentrations (unpublished results), which highlights its anabolic potential. When considering 
the digestion and absorption of dipeptides—coupled with the anabolic potential of leucine—
dileucine may prove to have an impact on skeletal muscle metabolism. 
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CHAPTER 3: METHODOLOGY 
The goal of the overall study design was to compare the anabolic properties of ingesting leucine 
or dileucine in healthy young adults. To accomplish this, a double-blind, randomized crossover 
study was completed in which participants were randomized to ingest either 2.00g of leucine 
(LEU) or 2.47g of  dileucine (DILEU). A primed constant infusion of L-[ring-13C6]- and [
15N]-
phenylalanine with concurrent muscle and blood samples was done to determine MPS and MPB 
rates of skeletal muscle in the resting state. 
3.1 Participant Recruitment 
Ten young physically active males were recruited to participate in this investigation. All 
participants were informed of the investigation’s purpose, experimental procedures, risks, and 
benefits before providing written informed consent (Appendix A). To ensure participants met 
inclusionary criteria, all participants completed a medical history and physical activity 
questionnaire (Appendix B & C, respectively). All subjects were recruited through 
advertisements on dedicated bulletin boards within the University of Illinois, online newsletter 
advertisements (e.g. Eweek), social media, and word of mouth. This investigation conformed to 
the Helsinki Declaration and was approved by the local research ethics board of the University of 
Illinois at Urbana/Champaign. This investigation was registered with ClinicalTrials.gov 
(NCT03952884).  
Inclusion and exclusion criteria 
Males between 18-35 years old were included in this investigation if they were deemed to 
be physically active in the 6 months leading up to their participation in the study (>30min of 
moderate physical activity, >3 times/wk). Participants were excluded from participation if they 
had a known cardiovascular, pulmonary, or metabolic disease(s) or a related sign or symptom. 
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Moreover, individuals were excluded if they had: 1) a musculoskeletal injury within the six 
months prior to the study; 2) participated in an amino acid infusion trial in the previous year; 3) 
followed a non-traditional eating pattern (i.e. vegetarian, vegan, ketogenic diet); 4) consumed 
ergogenic levels of dietary supplements that may affect muscle mass (e.g. creatine, HMB), 
insulin like substances, or anabolic hormones within 6 months prior to participation; 5) 
consumed a thyroid, androgenic, or other medication known to affect endocrine function, and; 6) 
consumed medications known to affect protein metabolism (e.g. prescription-strength 
corticosteroids, non-steroidal anti-inflammatories, or acne medication).  
3.2 Experimental Design 
Preliminary tests 
Participants completed a full-body dual x-ray absorptiometry (DXA) scan. Scans were 
then analyzed for fat mass, bone mass, lean body mass, and body fat percentage. Participants 
also completed a static handgrip strength assessment using a hand dynamometer, a proxy for the 
characterization of muscular strength (65,66). 
Diet and physical activity control  
Participants were instructed not to modify their exercise and dietary habits immediately 
before or during their participation in the study. Participants complete a two-day dietary recall 
using an online database (ASA24, version 2016, National Cancer Institute, Bethesda, MD, USA) 
for the two days leading up to their first trial. Participants were given a printout of the meals they 
logged and were asked to replicate the diet before the second trial. All participants were given a 
standardized meal to consume on the night before each trial. This meal accounted for 25-30% of 
their estimated caloric needs and had a macronutrient distribution of 25% protein, 25% fat, and 
50% carbohydrate. Participants were requested to consume only water during the 10hrs before 
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each trial. Additionally, participants were asked to refrain from vigorous exercise for 72hrs 
before each trial and refrain from alcohol, caffeine, and over-the-counter medications for 24hrs 
before each trial. Participants were asked to have a full night of sleep and arrive at the laboratory 
via car or public transportation. Adherence to the pre-trial instructions was checked via a pre-
trial questionnaire administered upon arrival to the laboratory. 
Experimental Design  
Participants partook in a double-blind, randomized crossover design investigation. 
Participants performed two infusion trials—which occurred at the same time of day (± 1 hr) for 
each participant—separated by at least 7 days. Each trial consisted of a 3hr lead-in followed by 
the ingestion of one of the two protein beverages (Figure 3.1). One drink consisted of 2.00g of 
pure LEU (L-Leucine, NNB Nutrition, Frisco, TX). This amount has been demonstrated to be 
sufficient to stimulate rates of MPS (16). The second beverage consisted of 2.47g of DILEU 
(DiLeucine, NNB Nutrition, Frisco, TX). Both beverages were dissolved in 150mL of water on 
the day of the trial. 
 
Figure 3.1: Study Timeline 
Infusion and sampling protocol 
Upon arrival to the laboratory, the participant’s weight and blood pressure were 
measured. A Teflon catheter was then inserted in an antecubital vein of the left arm. After taking 
a baseline blood sample, a primed (2.0 µmol·kg-1) continuous infusion (0.05 µmol·kg-1·min-1) of 
L-[ring-13C6]phenylalanine and [
15N]phenylalanine was initiated in one catheter. The isotopes 
(Cambridge Isotope, Inc., Andover, MA) were dissolved in 0.9% saline, filtered through a 0.2-
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µm filter, and infused using a calibrated syringe pump (Harvard Apparatus, Holliston, MA). A 
second catheter was inserted in an antecubital vein of the other arm for arterialized blood 
sampling. The catheter was kept patent throughout the trial using a 0.9% saline drip. A 180min 
lead-in was done during each trial, with arterialized blood samples collected at -180, -120, -60, 
and -30 min. After arterialized blood and muscle samples were collected at 0min, participants 
ingested one of the two test beverages and commenced a 180min postprandial period. The 
[15N]phenylalanine tracer infusion was terminated upon consumption of the protein beverage for 
the measurement of MPB within the first 60mins of the postprandial period. Additional 
arterialized blood samples were taken at 15, 30, 45, 60, 90, 120, and 180 min after consumption 
of the test beverage (Figure 3.2). Percutaneous muscle biopsies of the vastus lateralis were 
collected at 0, 30, 60 and 180 min after beverage ingestion using a Bergstrom needle (modified 
for manual suction) under 2% xylocaine local anesthetic. Biopsies for the first trial were 
collected from the dominant leg—biopsies were collected from the non-dominant leg during the 
second trial. All muscle biopsies except for those at 30 and 60 min were taken from separate 
incisions. Each incision was approximately 4–5 cm proximal from the first incision site, which 
was made ~10 cm above the knee. Samples were cleaned of any fat or fascia and were 





Figure 3.2: Primed, constant stable isotope amino acid infusion and sampling timeline. Participants consumed either 2.00g of pure 




3.3 Sample Processing and Analysis 
Plasma samples were analyzed for the quantification of insulin and glucose 
concentrations. Muscle and plasma samples were processed to determine: 1) muscle enrichment 
for the calculation of FSR; 2) muscle intracellular concentration and enrichment for FBR, and; 3) 
plasma enrichment of phenylalanine for the calculation of FSR and FBR. A concise account of 
the methods used is provided below. A more detailed account of the methods used are provided 
in Appendix D, E, F, & G. 
Plasma Glucose and Insulin Analysis 
10mL of venous blood was collected into an EDTA-coated tube (K2 EDTA, BD 
Vacutainer®, Franklin Lakes, NJ) that was chilled on ice. The blood samples were subsequently 
centrifuged at 3000 × g for 10min at 4°C, aliquoted, and stored at -80°C until further analysis. 
Blood plasma glucose concentrations were analyzed using a 2300 Stat Plus glucose analyzer 
(YSI Life Sciences, Springs, OH). Plasma insulin concentrations were determined using a 
commercially available immunoassay kit (ALPCO Diagnostics, Salem, NH). Concentrations 
were determined by fitting data to a four-parameter standard curve. 
Measurement of Myofibrillar Muscle Protein Synthesis (MYO)  
Muscle samples (~50mg) were weighed using a precision scale and homogenized using a 
Teflon mortar and pestle on ice. Samples were homogenized using a RIPA buffer solution at a 
ratio of 10µL buffer/1mg wet muscle. The resulting homogenates was centrifuged at 700 x g for 
15min at 4°C. The resulting pellet was used for the quantification of MYO protein enrichment. 
MYO pellets were washed with ddH2O and centrifuged. 0.3 M NaOH was added to the samples 
to facilitate the separation of the myofibrillar fraction from the collagen fraction by heating and 
centrifugation. 1 M PCA was added to the samples, resulting in a precipitate, and pelleted.  
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Samples were washed with 70% EtOH and hydrolyzed overnight at 110°C with 6 M HCl. 
Free amino acids were purified using cation exchange chromatography on Dowex resin columns 
(Dowex 50WX8-200 resin; Sigma-Aldrich Ltd) and dried down using a Speedvac (Savant 
SC250EXP, Thermo Scientific, Waltham, MA: heat time: 2hr; run time: 6hr at 45 °C; vacuum: 
1.1). Samples were analyzed by liquid chromatography–mass spectrometry (LC-MS/MS). 
Plasma Analysis for Single Biopsy Approach  
The free mixed muscle protein pool was extracted from 200µl of plasma by adding 100% 
acetonitrile. Samples were subsequently washed with ddH2O, and subsequently 70% EtOH. 
Samples were freeze dried (BT85A, Millrock Technology, Kingston, NY) and the resulting 
pellets were treated as muscle samples from this point forward. Samples were purified using 
cation exchange chromatography on Dowex resin columns (Dowex 50WX8-200 resin; Sigma-
Aldrich Ltd) and dried down using a Speedvac (Savant SC250EXP, Thermo Scientific, 
Waltham, MA: heat time: 2hr; run time: 6hr at 45 °C; vacuum: 1.1). 
Plasma Amino Acid Enrichment and Amino Acid Quantification 
Samples were thawed and vortexed prior to analysis. Pure methanol was added to 50μL 
of sample, vortexed for 10secs, and centrifuged. 10μL of DL-p-Chlorophenylalanine internal 
standard was added before drying via Speedvac (45°C, 2 hr (heat time), 8 hours (run time)). 
Samples were re-suspended with 1mL of 0.1% formic acid and analyzed using LC-MS/MS. 
Muscle Intracellular Amino Acid Concentration  
Muscle samples were homogenized using a Teflon mortar and pestle with 0.6 M PCA 
and centrifuged. The resulting supernatant—containing the IC pool—was subsequently pipetted 
off. 0.6 M PCA was added to the remaining pellet and centrifuged two more times. Samples 
were purified using cation exchange chromatography on Dowex resin columns (Dowex 50WX8-
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200 resin; Sigma-Aldrich Ltd) and dried down using a Speedvac (Savant SC250EXP, Thermo 
Scientific, Waltham, MA: heat time: 2hr; run time: 6hr at 45 °C; vacuum: 1.1). 
Calculation of Fractional Synthetic and Breakdown Rate 
The myofibrillar protein FSR, a direct measurement of MPS, was calculated at isotopic 
plateau using the standard precursor–product method. MPS was calculated using the following 
equation: 
(%h-1) = (ΔEm/Ep x 1/t) x 100 
Where ΔEm is the change in the isotopic enrichment of the myofibrillar proteins between 
biopsies, Ep is the mean isotopic enrichment of the intracellular amino acid precursor pool, t is 
the incorporation time between biopsies (h), and 100 is a constant to convert the calculated 
proportion of muscle synthesized per hour to a percentage of muscle synthesized per hour.  
The mixed muscle FBR, a direct measurement of MPB, was calculated using the two-
precursor pool adaptation of the precursor–product method. Briefly, the tracee dilution method 




Here P = EM/(EA - EM) at isotope plateau, EA and EM are isotope enrichment in the 
arterialized pool and IC pool, respectively; EM(t2) – EM(t1) is the change of enrichment in the IC 
pool from time 1 (tI) to time 2 (t2) after stopping the isotope infusion; ∫EA(t)dt and ∫EM(t)dt are 
areas under the decay curves of arterial enrichment and IC pool enrichment, respectively, from t1 
to t2. QM/T is the ratio of intracellular free tracee content versus protein-bound tracee content in 
the muscle. The ratio of the free amino acid pool size to the bound amino acid pool size (QM/T) 







3.4 Statistical Analysis 
 Differences in plasma glucose and insulin concentrations, plasma leucine and dileucine 
concentrations, MPS rates, and MPB rates were calculated using a two‐factor (condition × time) 
analysis of variance (ANOVA) with repeated measures on time. Where significant interactions 
were identified in the ANOVA, Tukey's post hoc test was performed to determine differences 
between means for all significant main effects and interactions. The level of statistical 
significance was set at P < 0.05 for all analyses. The data are expressed as mean ± standard error 
of the mean (SEM). All analyses were performed with IBM SPSS Statistics (version 23, IBM 
Corporation, Armonk, New York).
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CHAPTER 4: RESULTS 
This chapter outlines the results of this investigation as outlined in this thesis. 
Table 4.1: Participant Characteristics 
Variable  
     Age (y) 23 ± 1 
     Height (cm) 178.2 ± 1.6 
     Weight (kg) 77.1 ± 2.9 
     Body Mass Index (kg/m2) 24.2 ± 0.6 
     Lean Body Mass (kg) 55.0 ± 1.9 
     Fat Mass (kg) 17.4 ± 1.5 
     Body Fat % 22.8 ± 1.1 
     GLTEQ2 Score 64 ± 8 
     Blood Pressure (Systolic/Diastolic, mmHg) 118 ± 3 / 72 ± 3 
     Handgrip Strength3 (kg) 92 ± 6 
1Data is represented as Mean ± SEM.  
2GLTEQ, Godin Leisure-time Exercise Questionnaire 
3Handgrip strength is quantified as the sum of left and right handgrip scores 
 
Effect of LEU and DILEU on MPS and MPB 
 The FSR representing MPS of myofibrillar protein is represented in Figure 4.1. FSR for 
LEU was increased from fasted value of 0.048 ± 0.003%·h-1 to 0.078 ± 0.059%·h-1 30min after 
LEU ingestion (main effect of time, P < 0.0001). FSR values at 180min were not different from 
baseline values (0.047 ± 0.009%·h-1, P = 0.949). DILEU significantly increased FSR from a 
baseline of 0.048 ± 0.003%·h-1 to 0.122 ± 0.053%·h-1over the 1hr postprandial period (main 
effect of time, P < 0.0001). Unlike LEU, DILEU maintained elevated rates of FSR 3hr after 
ingestion (main effect of time, 0.075 ± 0.009%·h-1 , P = 0.025). DILEU had a significantly 
higher increase in MPS when compared to LEU over the 3hr postprandial period (main effect of 
condition, P < 0.05). The FBR representing MPB of mixed muscle protein is represented in 
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Figure 4.1. DILEU ingestion resulted in a 18.6% increase in MPB when compared to LEU 
ingestion—however there was not a significant difference between conditions across the 60min 
postprandial period (LEU, 0.043 ± 0.011%·h-1; DILEU, 0.051 ± 0.010%·h-1, P = 0.659). 
 
Figure 4.1: FSR rates at basal and across the 3hr postprandial period (A) and FBR rates 60mins 
after ingestion of LEU or DILEU beverages (B). Data are expressed as means ± SEM. FSR, 
Fractional Synthetic Rate, FBR, Fractional Breakdown Rate. *Significant difference from basal, 






Effect of LEU and DILEU on plasma leucine and dileucine concentrations 
 Leucine plasma concentrations increased from 86 ± 10 mmol·L-1 to 223 ± 23 mmol·L-1 
by 15min after ingestion in the LEU condition (Figure 4.2, main effect of time). Values remained 
significantly elevated from baseline through the first 60mins of the postprandial period (P < 
0.05). The DILEU condition followed a similar trend, with plasma leucine increasing from 91 ± 
7 mmol·L-1 to 238 ± 19 mmol·L-1 by 15min after ingestion and remained elevated 1hr after 
ingestion (main effect of time, P < 0.05). There was not a significant difference between 
conditions (P < 0.05). 
 Dileucine plasma concentrations increased from 0.0003 ± 0.0001 μmol·L-1 to 0.0070 ± 
0.001 μmol·L-1 by 30min after ingestion of LEU (Figure 4.2, main effect of time). Values were 
not significantly different from baseline through any point in the 3hr postprandial period (P > 
0.05). DILEU ingestion increased dileucine plasma concentrations from 0.0006 ± 0.0001 
μmol·L-1 to 0.020 ± 0.003 μmol·L-1 by 15min after ingestion. Concentrations remained 
significantly elevated through 30min (main effect of time, P < 0.05) before returning to values 
not statistically different from baseline. There was a significant difference between conditions at 
15min (P = 0.008) and 30min (P = 0.003) postprandially between conditions (Figure 4.2, main 




Figure 4.2: Average plasma leucine (A) and dileucine (B) concentrations during the time course 
of the infusion trial in the LEU and DILEU groups. 0min denotes the beginning of the 
postprandial period. Data are expressed as means ± SEM. *Significant difference from baseline, 







Effect of LEU and DILEU on plasma insulin and glucose concentrations 
 Plasma insulin responses to LEU ingestion resulted in a non-significant increase 15min 
postprandially from baseline (6.8 ± 1.4 μUI·mL-1, P > 0.05). DILEU ingestion resulted in similar 
plasma insulin responses—there was an increase from baseline at 15min (7.2 ± 1.0 μUI·mL-1, P 
< 0.05) postprandial but was not significant from baseline. There was not a significant difference 
between LEU and DILEU conditions at any time point (Figure 4.3, no effect for condition, P > 
0.05). For both LEU and DILEU conditions, there was not a significant increase in plasma 
glucose concentrations (Figure 4.3) from baseline (LEU, 81.5 ± 1.5 mg·dL-1; DILEU, 80.7 ± 2.0 
mg·dL-1) postprandially (P < 0.05). There was also no significant difference between conditions 




Figure 4.3: Average insulin (A) and glucose (B) concentrations during the time course of the 
infusion trial. 0min denotes the beginning of the postprandial period. There was no significant 





CHAPTER 5: DISCUSSION 
 The study presented within this thesis suggests that DILEU stimulates increases in MPS, 
but does not modulate MPB, when compared to LEU. To our knowledge, we are the first group 
to report findings on muscle protein turnover (MPS and MPB) to dipeptides in humans. 
Interestingly, a quantity of DILEU (2.47g), which is similar to a quantity of LEU contained in 
whole food dietary protein sources (2.00g), stimulated a ~60% difference in MPS. There was no 
difference in MPB between the LEU and DILEU conditions. In turn, these results show the 
potential of DILEU, and more broadly dipeptides, to enhance MPS and net protein balance 
Dipeptides are absorbed in the small intestine almost exclusively by PEPT1 (32,67), and 
have been shown to enter peripheral blood circulation intact shortly after ingestion (30). Here, 
we show that plasma leucine concentrations did not differ between the LEU and DILEU 
conditions. This suggests that the ingested dileucine was partially hydrolyzed. However, we 
observed an elevation in plasma dileucine concentrations in the DILEU condition when 
compared to the LEU condition. This finding provides support for the notion that dipeptides may 
transfer intact into circulation and may have a role in regulating the postprandial stimulation of 
human MPS. With that said, it is unclear from these results what the mechanism behind 
dileucine’s greater anabolic potential may be. Speculatively, dileucine could have activated the 
mTOR signaling pathway and its downstream targets to a greater extent than leucine. This may 
be a result of dileucine’s reliance on a different set of absorption pathways, which ultimately led 
to greater circulating leucine either in the form of free leucine or as dileucine. All told, more 
work should be initiated to determine dileucine’s impact on anabolic signaling and clarify the 
potential mechanisms behind its anabolic potential.  
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 Leucine ingestion did not result in increased rates of MPS from baseline values. The 
inability to stimulate MPS could be attributed to providing a dose that was too low to initiate an 
anabolic response. The only study measuring the human skeletal muscle protein synthetic 
response to leucine that reported a rise in MPS was with a dose of 3.0g of pure leucine (14). 
Additionally, a culmination of literature points to a potential “leucine threshold” theory, which 
suggests that a dose of 2.5 – 3.0g of leucine is needed to stimulate MPS (68,69). That said, a 
study using 1.8g of leucine as part of a 10g EAA beverage was able to stimulate MPS rates to a 
similar degree as a 10g EAA beverage containing 3.0g of leucine (16). In turn, the anabolic 
potential of leucine—especially at lower doses—may be maximized when incorporated as part of 
a mixed meal. Methods using small, continuous boluses (20,22,56–58) and a single bolus of 
leucine (14,16,17,21) in conjunction with carbohydrates and/or EAA have all resulted in 
increased rates of MPS.  
Against our hypothesis, we report no differences in MPB between conditions 60mins 
after ingestion. Due to methodological limitations, we were unable to measure basal rates of 
MPB in our cohort. However, basal MPB rates obtained previously using the tracer dilution 
method in a cohort with similar baseline characteristics reported basal rate of  0.11 ± 0.01 %×h-
1(44). With these basal rates as a reference, LEU and DILEU ingestion may both have decreased 
rates of MPB. Postprandial insulin secretion has been confirmed to decrease rates of MPB after 
administration of amino acids (70–73). When systemic insulin concentrations are increased to 
both fed and physiologically high concentrations (~30-170 μUI·mL-1), MPB rates do not 
decrease in a dose-dependent manner. Moreover, when insulin is maintained at fasted 
concentrations (~5.0 μUI·mL-1), rates of MPB are unchanged despite amino acid infusion 
replicating a high dietary protein source (70). Both LEU and DILEU beverages failed to increase 
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plasma insulin—and for that matter plasma glucose—concentrations above fasted values. As 
such, it is likely that insulin played a negligible effect on rates of MPB in this cohort. This 
investigation did not calculate net protein balance because the methodological limitation of the 
tracer infusion method—which relies on the mixed muscle protein pool (e.g. myofibrillar, 
sarcoplasmic, mitochondrial, etc.) for the calculation of MPB. The method we used to calculate 
MPS utilizes the myofibrillar protein fraction, which directly targets rates of skeletal MPS. 
Nonetheless, we are the first to report rates of MPB induced by dipeptide ingestion in vivo in 
humans.  
Previous literature has highlighted that rapid increases in blood leucine concentrations are 
followed by increases in resting MPS values, which suggests that protein digestion and 
absorption rates represent an important factor in the nutritional regulation of MPS in humans 
(74). Oral ingestion of DILEU did not further elevate plasma leucine concentrations when 
compared to LEU ingestion. DILEU ingestion resulted in higher concentrations of dileucine 
plasma concentrations within the first 30mins after ingestion. Dipeptides have been suggested to 
pass through digestion and absorption intact (30,31), but this has now been shown to be 
dependent on the structural characteristics of the dipeptide (31). To date, it is unknown if the 
postprandial appearance of dipeptides in circulation constitutes an overflow mechanism or if this 
has a physiological function (32). Regarding the latter idea, multiple tissues express peptide 
transporters and cytosolic peptidases that enable them to absorb and metabolize peptides. 
However, the presence of such peptide transporters in skeletal muscle have not been explored 
(75). There are multiple reasons why a dipeptide may or may not become detectable in peripheral 
blood. Among them are that the peptide is taken up by PEPT1 into enterocytes followed by rapid 
hydrolysis via cytosolic peptidases or that the peptide is resistant to hydrolysis and reaches 
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circulation intact but is rapidly hydrolyzed by endothelial or plasma peptidases (32). The 
detection of dipeptides in peripheral circulation could also result from intracellular protein 
turnover whereby proteins may not be hydrolyzed entirely to free amino acids. Rather, proteins 
might escape hydrolysis and reach circulation, just like dietary dipeptides absorbed by PEPT1. 
This may partially explain the presence of dileucine concentrations detected during the LEU 
condition and during the fasted state of both trials (32). All told, our data suggest that dileucine 
likely has a high affinity for hydrolysis in the enterocyte and entered peripheral circulation 
primarily as free leucine.  
Leucine ingestion has been reported to result in the postprandial secretion of insulin and 
is suggested to be an insulin secretagogue (76). Against our hypothesis, we report that neither 
LEU nor DILEU ingestion resulted in significant rises in postprandial plasma insulin 
concentrations. However, there was a non-significant rise in plasma insulin in the first 15min 
after ingestion—suggesting that leucine indeed increases insulin values, but was not given in a 
large enough dose to achieve a significant elevation in this cohort. Insulin responses in this 
investigation are similar to the response reported by Wilkinson et al. (14), who reported increases 
in insulin concentrations within the first 30mins after leucine ingestion before returning to levels 
not significant from baseline. DILEU was able to stimulate a similar postprandial insulin 
response to LEU, suggesting that the different digestion and absorption routes dipeptides pass 
through do not alter the insulin responses characteristic of amino acids. Glucose responses to 
both LEU and DILEU ingestion did not significantly deviate from baseline values. These data 
are in line with previous findings that found no changes in glucose concentrations after ingestion 
of free amino acids in healthy adults (77). As such, these data suggest DILEU does not pose any 
additional benefit to postprandial insulin and glucose responses when consumed alone. 
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Despite these promising findings, the limitations of this investigation must be 
highlighted. Specifically, these data do not include measures of signaling protein activation for 
either beverage condition. Targeting signaling protein activation (specifically p70S6K, 4E-BP1, 
etc.) would give us a deeper look into what these dietary proteins—particularly dileucine—is 
doing at the mechanistic level and what is mediating its anabolic potential. This study did not 
fully account for the impact that insulin may have on rates of MPB. Insulin has been shown to 
mitigate MPB (70,73), leading other investigators to refrain from measuring MPB rates after 
leucine ingestion (14). Controlling for insulin—such as through a hyperinsulinemic euglycemic 
clamp—would provide insight into whether dileucine’s impact on skeletal muscle protein 
turnover is insulin mediated or independent of insulin. That said, this would be difficult to do 
without the proper infrastructure in place and would place participants at a higher degree of 
discomfort. Another limitation was that our study participants were limited to healthy, physically 
active, young males. In turn, these data only apply to a subsection of the general population—
failing to address other sections of the general population that have varying dietary needs (e.g. 
older adults, women, etc.). Lastly, for this investigation, we did not extract the mixed muscle 
protein pool for the calculation of FSR—preventing us from making a calculation of net protein 
balance.  
  In summary, the results of this investigation demonstrate the ability of dileucine to 
stimulate increases in MPS at rest in healthy young males. Moreover, this is the first study to 
characterize the role that dipeptides play in the regulation of muscle protein turnover in vivo in 
humans. When considering that dileucine was provided at a near equivalent dose as leucine, 
these data allude to the enhanced anabolic potential that dileucine, and dipeptides as a food 
component, possess.  
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CHAPTER 6: GENERAL CONCLUSIONS 
 The data presented in this study demonstrate that dileucine stimulates increases in MPS 
rates after 3hrs to a greater extent than leucine in healthy, physically active young males. This is 
demonstrated by the 59.8% difference in fractional synthetic rates between dileucine and leucine 
after equivalent doses were ingested. Moreover, these data show that a dose of dileucine similar 
to a suboptimal dose of leucine is able to stimulate MPS rates to a similar degree as an optimal 
dose of leucine. Lastly, the data in this study provide preliminary support for the use of dileucine 
as a way to fortify foods for the enhancement of skeletal muscle mass and quality. 
Future directions of this work should aim to address the limitations of the current 
investigation. Specifically, future work should be done to understand how dileucine impacts the 
mTOR signaling pathway and its downstream targets. Probing how dileucine impacts these 
signaling proteins will give further insight into how this compound stimulates MPS and inhibits 
MPB. A future study should incorporate an exercise component to the current study protocol. 
Exercise has been demonstrated to potentiate MPS rates when leucine is consumed after exercise 
(17,21,57). The data presented are only representative of skeletal muscle protein responses in the 
resting state—indicating a gap in the literature and warranting future exploration This study 
provided amino acids in isolation (i.e. no other macronutrient was ingested). While this is 
necessary to determine the effect of novel found compounds on muscle protein turnover, this is 
not a practical suggestion to make for the lay individual. Future investigations should aim to 
determine how dileucine—when included as part of a mixed meal—influences muscle 
metabolism. Previous studies have added leucine to a mixed meal and have shown robust 
increases in MPS (21,57). Lastly, future work should aim to replicate this work in older adults—
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a population characterized as having resistance to anabolic stimuli like dietary protein and 
resistance exercise. 
It is evident from these data that other dietary amino acid components aside from free 
amino acids can produce positive shifts in muscle protein turnover. This has encouraging 
implications for future strategies aimed at enhancing skeletal muscle mass and quality across 
general and clinical populations. Particularly, dipeptides could be a promising dietary 
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APPENDIX A: INFORMED CONSENT FORM 
INFORMED CONSENT  
Title of project  
Skeletal muscle protein synthetic response to amino acid and dipeptides  
Key Information  
The purpose of this study is to understand the effects of amino acid peptides ingestion on muscle 
growth and breakdown at rest and after resistance exercise. Participating in this study will 
involve one pre-testing session (3 h) and two testing sessions (6.5 h each). During testing 
sessions, you’ll be randomized to either 1) consume a protein drink only; or 2) consume a protein 
drink and perform a bout of resistance exercise. Blood and muscle samples will periodically be 
taken throughout each testing session. Benefits related to this research include gaining 
information about your body composition (Lean mass, body fat and bone density) and learning 
how you respond to acute exercise and nutritional stimuli.  
Introduction  
This form contains information about this study and it is necessary that you understand its 
contents prior to enrolling in this study. Please ask any questions you may have about the 
research; we are happy to explain anything in greater detail. You will be provided with a copy of 
this form to take with you. For this study, we are interested in how people respond to individual 
amino acids and dipeptides, with or without resistance exercise.  
Please contact members of the research team with any questions you may have about the study:  
Rafael A. Alamilla, BS    Amadeo F. Salvador, MS  
Kinesiology & Community Health, UIUC   Kinesiology & Community Health, UIUC  
106 Louise Freer Hall,    352 Louise Freer Hall,  
906 S. Goodwin Avenue   906 S. Goodwin Avenue   
Email: 
NutritionExerciseResearch@gmail.com 
Tel.: 217-244-9905  
Email: naburd@illinois.edu  
Kevin J.M. Paulussen, MS  Colleen McKenna, MS, RD  
Kinesiology & Community Health, UIUC   Division of Nutritional Sciences, UIUC  
106 Louise Freer Hall,    106 Louise Freer Hall,    
906 S. Goodwin Avenue   906 S. Goodwin Avenue   
Email: NutritionExerciseResearch@gmail.com  Email: NutritionExerciseResearch@gmail.com  
Tel.: 217-244-9905  Tel.: 217-244-9905  
Nicholas Burd, PhD  Dr. Scott Paluska, MD  
Kinesiology & Community Health, UIUC  Department of Orthopedics, Christie Clinic  
352 Louise Freer Hall,    1405 West Park Street Suite 200  
906 S. Goodwin Avenue   Urbana, IL 61801  
Email: naburd@illinois.edu  Email: paluska@illinois.edu  
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If you wish to report a research related injury, please contact Dr. Nicholas Burd at the listed 
phone number or e-mail as soon as possible. This should be done within 24 hours of discovering 
the injury.  
This study is expected to last for the next year, but your involvement will only last about 2 
weeks.  You will be invited to the lab on three occasions consisting of: one screening, two 
experimental days. 
Pre-Test Procedures  
Prior to the intervention, you will visit the laboratory at Louise Freer Hall, UIUC for one 
screening (time commitment: ~1.5 h). During, we will determine if you are eligible for this 
research study. If it is determined that you are not eligible for the study, your paperwork and data 
will be destroyed. The researchers will give you a detailed explanation of each procedure during 
the screening. However, the following information will give you an overview:   
1. Medical history, physical activity readiness, & physical activity habits. You will be asked 
to complete a medical history and physical activity readiness questionnaire. Additionally, 
you will complete a questionnaire that asks about your current physical activity habits. 
We will also review your answers to ensure you are eligible and that it is safe for you to 
participate in this study. 
2. Blood pressure. We are only enrolling participants with healthy blood pressure for this 
study. 
3. Body weight and height. With these measures we will calculate your BMI. 
4. Body composition. We will use a DXA scan (Dual-energy X-ray Absorptiometry) to 
determine your fat mass, bone mass, and muscle mass. For this scan, you have to remove 
all metal from your body such as jewelry or watches. You will be required to lie on your 
back on a padded table. This test lasts about 15 minutes. 
Women: If you are pregnant we will have to exclude you from participating to avoid 
unnecessary radiation exposure. 
5. Maximal Strength Testing. A ten repetition maximum (10-RM) will be determined for the 
leg extension exercise, which will be used to calculate their workload for experimental 
days. 10-RM will be defined as the point at which the participant can no longer increase 
weight of resistance while maintaining proper form for ten consecutive repetitions.  
Handgrip strength on both hands will also be tested using a small machine that you will 
squeeze as hard as you can in order for us to measure your grip strength. 
Afterwards, the research team will randomize you into one of two groups: a) exercise; or b) non-
exercise. If assigned to the exercise group, you will perform the exercise outlined below. 




APPENDIX A: INFORMED CONSENT FORM (Cont.) 
Experimental Days  
You are asked to participate in two trial days, lasting approximately 6.5 h each. Detailed 
explanations of each procedure is provided below. During the screening and testing day, 
researchers will explain every procedure in detail.  
1. Preparations. 
Exercise: You are expected to abstain from alcohol consumption and strenuous physical 
exercise for the 72h (3 days) leading up to each experimental trial day. “Strenuous” 
activities include weight lifting (upper and lower body), cycling, running, and 
competitive sports (soccer, basketball, etc.). On the morning of the experiment, we ask 
that you arrive to Freer Hall by public transport or car (cycling, walking is unacceptable) 
without breakfast/caffeine (coffee, tea, etc.). 
Diet: For the 48 h (two days) leading up to each experimental trial, you will be asked to 
record all consumed food and beverages through an online portal, Automated Self-
Administered Recall System (ASA 24), developed by the National Cancer Institute. We 
ask that you repeat the same dietary habits for the 48 h leading up to the second trial. 
Confidential, non-identifiable, login information will be provided in order to access the 
dietary recording website. The evening prior to test days, you are asked to eat a provided 
meal no later than 10:00 pm. After that time, we ask that you remain fasted (no food, 
regular amount of water is OK) through the experimental day. 
2. Blood Collection. On the test day, a small catheter (flexible plastic tube) will be inserted 
into a hand vein to allow for blood sampling. The catheters will be inserted with the 
assistance of a small needle. The needle will not remain in your hand, but only the 
flexible plastic tube. The discomfort felt during this procedure passes quickly and feels 
similar to donating blood. To minimize discomfort, a numbing cream will be used prior 
to the catheter placement. Once the needle is removed you should not feel the catheter.  
  
During the test day, blood will be drawn periodically from the catheter in the hand vein. 
Before drawing the blood samples, your hand will be placed into a heated blanket 
warmed to 60°C. A total of ~3 oz. of blood will be drawn over the entire test. For 
comparison, when you donate blood, ~17 oz. is drawn in a minute.   
  
After each sample is taken the catheter is "flushed" with a sterile saline solution in order 
to prevent blood from clotting in the catheter.  This is a salt solution similar in 
composition to your own blood and it will not affect you.  
  
3. Stable Isotope Infusion. A second catheter will be placed in a vein in your opposite arm 
for an infusion (long slow injection) of two amino acids. The amino acids will be 
dissolved in saline (a sterile salt solution similar to your blood). Our bodies use amino 
acids to make new proteins. By labeling an amino acid, we can see where these amino 
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labeled with a stable isotope of carbon—the other with a stable isotope of nitrogen. An 
isotope is slightly heavier form of this element. Since the isotope is stable (i.e., non-
radioactive), it poses no health risk to you due to radioactive exposure. A certain fraction 
of all of the carbon—and nitrogen—within your body is already in the same form as that 
of the stable isotopes used. Hence, the infusion of the stable isotope-labeled amino acids 
will simply result in a slight increase in the amount of stable isotope within your body; 
we refer to this as "enriching" the amount of stable isotope within your body.   
  
This enrichment will not remain high, however, and will be back to pre-infusion levels 
within a few days. The infusions are prepared under sterile conditions and are filtered 
through a very selective filter prior to entering your body. This solution does not contain 
anything that will adversely affect your health.  
  
4. Muscle Samples. During the test day we will take a small piece of muscle tissue (muscle 
biopsy) at four different time points by using a sterile hollow needle. For each biopsy, Dr. 
Burd will clean an area over your thigh muscle and inject a small amount of numbing 
solution (lidocaine) into and under the skin. He will then make a small incision (~4-5 
mm) in the skin in order to insert a sterile needle into your thigh. Dr. Burd will quickly 
remove a very small piece of muscle (~50-100 mg; which is about the size of a corn 
kernel) and remove the needle from your leg. During sample collection (~30 sec), you 
may feel the deep pressure in your thigh and on some occasions it may feel painful. 
However, the discomfort subsides very quickly. Following the biopsies, the incisions will 
be closed with sterile bandages.    
  
After leaving the laboratory, you are encouraged to perform light exercise (cycling, 
jogging) and daily activities. However, you should refrain from excessive muscle use for 
the remainder of the day. Namely, weightlifting sessions that involve deep squatting 
motions should be avoided for that day. Once the numbing agent wears off, your leg may 
feel tight and often there is the sensation of a deep bruise or "Charlie Horse". The 
tightness in the muscle usually improves within 2 days. You will be provided with care 
instructions to take with you.  
  
5. Resistance Exercise. Before eating, you will perform resistance exercise.  For this you 
will perform a warm-up on the leg extension, then you will perform 3 sets of 10 
repetitions of the leg extension exercise. A trained member of the research team will be 
present during your exercise bout.  
  
6. Protein Beverage. You will consume one of two amino acid- or dipeptide-based nutrient 
solutions immediately following the exercise bout. Specifically, amino acids are the 
individual building blocks of dietary proteins, and dipeptides molecules consist of two 
amino acids –both of which occur in all food products containing protein. Your second 
experimental day, you will consume the other protein choice. Order of consumption 
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Risks and Benefits  
Benefits. There are no direct benefits from participating in this study, but after completion you 
will be given information about your body composition (height, weight, body fat, etc.), habitual 
dietary intake, and maximal strength. Additionally, we can provided information about your 
ability to metabolize protein upon request. You may wish to have this information evaluated by a 
health professional. However, your participation in this study will help us understand how our 
muscles respond to the protein that we eat in a meal. Understanding this process will ultimately 
help provide information for designing nutrition programs to prevent or reverse the loss of 
muscle mass. The maintenance of muscle mass is important for your metabolism as well as for 
removing fat and sugar from the blood.   
  
Risks. You are not expected to be in great risk from participation in this study. The potential risks 
involved in participating in this study are described below.  
  
1. Potential risks with the muscle biopsy procedure  
The muscle biopsies are routinely used in research and complications are rare provided 
that proper precautions are taken.  However, there is a risk of internal bleeding at the site 
of the biopsy, which can result in temporary bruising (1 in 30) lasting up to 5 days.  
Small lump may form under the site of the incision (~1 in 500), but this normally 
disappears within a few weeks by massaging the lump with your thumb. As with any 
incision there is also a slight risk of infection (~1 in 2,200). However, this risk is virtually 
eliminated through proper care. In very rare occasions there can be damage to a 
superficial sensory nerve, which will result in temporary numbness in the area (~1 in 
1,500) lasting up to 3 months. There is also an extremely remote chance that you will be 
allergic to the numbing agent; the chance of lidocaine allergy is currently unknown. Your 
muscle may feel sore for 1 or 2 days following the procedure, as if you have performed 
difficult exercise. However, this is normal and will pass.  While there is also a theoretical 
risk of damage to a small motor nerve (this is used to allow your muscle to move) of your 
thigh muscle, this has never been seen in past experiences.   
  
To minimize the risk of skin infection and facilitate proper healing, you will be provided 
with explicit written instructions (“Biopsy Care Kit”) that details the proper care of the 
wound.   
  
2. Potential risks involved with catheterization  
The insertion of catheters for blood sampling is a common medical practice and involves 
few risks if proper precautions are taken. The catheters are inserted under completely 
sterile conditions. However, there is a theoretical risk of infection. There is also a chance 
of internal bleeding if adequate pressure is not maintained upon removal of the catheter. 
This may cause some minor discomfort and could result in bruising/skin discoloration, 
which could last for up to a few weeks. There is also a possibility of dizziness and 
lightheadedness associated with blood draws. To reduce the risk of falling, you will be 
seated or lying down during and after the blood draw. Additionally, we will provide you 
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research team are trained in First Aid and are CRP certified. In very rare occasions, 
trauma to the vessel wall could result in the formation of a small blood clot, which could 
travel through the bloodstream and become lodged in a smaller vessel.  However, we 
have never experienced such a complication with catheter placement.  
  
3. Potential risks involved with stable isotope infusion  
Despite all precautions, there is a theoretical risk (less than 1 in 1,000,000) that you could 
have a rapid drop in blood pressure during the infusion due to some small bacterial 
contamination of the infusion solution (infusate). Such an effect would occur during your 
visit to the laboratory. This has never occurred in our experience.  
  
4. Potential risks involved with DXA scan  
The level of radiation emitted during a DXA is very low, <1 μSv. This is very minimal 
exposure compared to the total background radiation level per year in North America, 
which is approximately 3.0 mSv/year).  
  
5. Potential risks involved with resistance exercise  
There is a small risk of sustaining minor muscle, bone and/or tendon injury during 
exercise. In addition, you may experience a feeling of discomfort after the exercise bout 
due to intensified use of major muscle groups. There is a theoretical risk that heart 
irregularities or sudden death may occur during exercise. However, these events 
generally happen to people who already have heart conditions. If you have been 
diagnosed with any type of heart condition you cannot participate in this study. If, despite 
precautions, an emergency occurs during exercise; research staff is trained in first aid and 
CPR. Also, advanced life saving equipment (e.g. AED) will be immediately on hand to 
respond in any manner necessary; including calling 911 if deemed appropriate.  
  
6. Potential risks involved with protein beverage  
Beverages will be prepared with protein powder reconstituted in water.  Leucine is an 
amino acid found naturally in dietary protein. The 2g amino acid or peptide beverage is 
well within a safe quantity for healthy adults. Individuals with metabolic disorders that 
indicate reduced capacity to metabolize protein and/or amino acids will be excluded from 
participation.  
  
Injury and Liability  
If you have any questions or problems with severe soreness, bleeding, or if the biopsy site 
becomes red or warm to the touch, please contact any of the researchers (found at the top of this 
form). If you sustain an injury as a result of participating in this research project that requires 
medical treatment you are strongly advised to get that treatment. However, the treatment you 
receive is not free of charge, and we have not set aside money to pay for related injuries. The 
University of Illinois does not provide medical insurance coverage for participants in this 
research study. Also, the University of Illinois does not provide compensation for any injury 
sustained as a result of participation in this research study, except as required by law.  Signing 
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Confidentiality   
Will my study-related information be kept confidential?    
  
Yes, but not always. In general, we will not tell anyone any information about you. When this 
research is discussed or published, no one will know that you were in the study. However, laws 
and university rules might require us to tell certain people about you. For example, your records 
from this research may be seen or copied by the following people or groups:  
   
• Representatives of the university committee and office that reviews and approves 
research studies, the Institutional Review Board (IRB) and Office for Protection of 
Research Subjects;    
• Other representatives of the state and university responsible for ethical, regulatory, or 
financial oversight of research;    
• Federal government regulatory agencies such as the Office of Human Research 
Protections in the Department of Health and Human Services  
   
Some samples obtained during this study will be stored in the laboratory (maximum 15 years), 
and may be used for further research. These extra samples are used for determining isotopic 
enrichment analyses that need to be repeated, or conducting additional cellular/molecular 
analyses.  Also, when publishing, reviewers often ask for additional measures and these samples 
could be used for this as well. Instead of contacting you later, you are asked to indicate whether 
you will permit these samples to be used in future research by selecting the appropriate option at 
the bottom of this form.  
  
Voluntariness & Compensation  
Your participation in this study is voluntary. You may withdraw your consent and discontinue 
participation in this study at any time without penalty or loss of benefits to which you are 
otherwise entitled. The investigators reserve the right to withdraw you from the study if they 
believe that circumstances have arisen that warrants doing so.   
  
You will receive $200 upon full completion of the study. If participation in this study is ended 
early, you will be paid according to what was completed. Participation we be prorated $25 per 
biopsy. No compensation will be provided for the completion of the screening day.   
  
If you have any questions about your rights as a participant in this study or any concerns or complaints, 
please contact the University of Illinois Institutional Review Board at 217-333-2670 or via email at 
irb@illinois.edu   
  
My signature indicates that I understand the information provided in this form and 
voluntarily agree to participate in this study and, on the date provided, received a copy of this 
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As stated above, we would like to keep your data, blood samples and biopsies for possible 
(related) future research. Occasionally, when publishing our work, we are asked to provide more 
information to clarify our findings, which can require additional blood or tissue. If we must do 
so, your permission will not be asked for again. The samples will be kept for a maximum of 15 
years. Please check the box of your choice.  
  
I do authorize the researchers to use my data, blood samples and biopsies for future research  
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In this excerpt from the Godin Leisure-Time Exercise Questionnaire, the 
individual is asked to complete a self-explanatory, brief query of usual 
leisure-time exercise habits.  
CALCULATIONS  For the first question, calculate weekly frequencies of strenuous (× 9), 
moderate (× 5), and light (× 0), activities. Total weekly leisure activity is 
calculated in arbitrary units by summing the products of the separate 
components, as shown in the following formula:  
Weekly leisure activity score = (9 × Strenuous) + (5 × Moderate) + (0 × 
Light)  
The second question calculates the frequency of weekly leisure-time 





EXAMPLE    Strenuous = 3 times/wk  
   Moderate = 6 times/wk  
   Light = 14 times/wk  
  




1. During a typical 7-Day period (1 week), how many times on the average do you do the following kinds 
of exercise for more than 15 minutes during your free time (write on each line the appropriate number).  
  
Times per Week  
  
STRENUOUS EXERCISE (HEART BEATS RAPIDLY)         ____________  
(eg, running, jogging, hockey, football, soccer, squash, basketball, cross country 
skiing,  judo, roller skating, vigorous swimming, vigorous long-distance bicycling)  
  
MODERATE EXERCISE (NOT EXHAUSTING)           ____________  
(eg, fast walking, baseball, tennis, easy bicycling, volleyball, 
badminton, easy swimming, alpine skiing, popular and folk 
dancing)  
  
MILD EXERCISE (MINIMAL EFFORT)             ____________  
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2. During a typical 7-Day period (1 week), in your leisure time, how often do you engage in any regular 
activity long enough to work up a sweat (heart beats rapidly)?  
  
  OFTEN   SOMETIMES   NEVER/RARELY  
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MEDICAL HISTORY QUESTIONNAIRE  
Skeletal muscle protein synthetic response to amino acid and dipeptides  
The following questions are designed to obtain a thorough medical history. The information you 
provide will help us to make the best determination about your eligibility for a particular study.  
Please answer all questions and provide as much information as you possibly can. This 
questionnaire will be kept confidential and will not be shared with any unauthorized person or 
organization.  
Subject ID  
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 Date of Birth  Age  Sex  
 
Previous research may disqualify you from participating in this research. If you have 
received stable isotopes previously, this would disturb our ability to measure protein 
synthesis. Please indicate you experience in research below.  
YES  NO  
Have you ever participated in a study where muscle biopsies were taken?    
Have you ever participated in studies with stable isotope amino acid tracers?    
Are you currently participating in any research studies?    
If you answered yes to any of the above, please describe:  
Personal Health History  
Have you ever been hospitalized or had surgery?    
Please list all hospitalizations and surgeries to the best of your recollection.  
Hospitalized for 
Disease/Operation  
Duration  Date of Hospitalization  
   
   
   
   






APPENDIX C: MEDICAL HISTORY QUESTIONNAIRE (Cont.) 
 YES  NO  
Are you allergic, sensitive, or intolerant of any medications?    
Are you allergic, sensitive, or intolerant of local anesthetic (pain killing medications; e.g., 
Novocaine, Lidocaine or Xylocaine)?  
  
Have you ever received an injection of a local anesthetic (pain killing medication; e.g., 
Novocaine, Lidocaine, or Xylocaine)?  
  
Are you allergic, sensitive, or intolerant of latex?    
Are you allergic, sensitive, or intolerant of any kind of tape or adhesive?    
Do you experience excessive scarring after injury (e.g., abrasions, piercings)?    
When you experience a cut do you take a long time to stop bleeding?    
Are you currently seeing a doctor or other health care provider for any reason?    
  




Do you have, or have you ever had any of the following conditions?  YES  NO  
Numbness of an arm or leg      
Weakness of an arm or leg      
Fainting or dizziness      
Lung or Respiratory Disease      
Rheumatism or arthritis      
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Epilepsy      
Tumors      
Mental illness      
Bleeding or clotting disorders      
Risk for infectious diseases (AIDS, IV drug use, blood transfusions, hemophilia, hepatitis)      
Do you have phenylketonuria (PKU)?      
High blood cholesterol      
Stomach: chronic indigestion, ulcer, hiatal hernia, heartburn, trouble swallowing, vomiting.      
Intestine: constipation, diarrhea, change in bowel habits, irritable bowel disorder, colitis, 
polyps.  
    
Liver, gallblader: hepatitis, gallstones      
Urinary: frequent urination, urgency, burning, pain, blood in urine, infection, kidney stones      
Have you ever had any form of cancer?      
Do you have diabetes mellitus (high blood sugar)?      
Have you ever been told that you had high blood pressure?      
Do you have any breathing problems, such as asthma?      
Do you have any chronic illnesses?      
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List all current or recent medications you may be taking, please include both prescription and 
over-the-counter (including ibuprofen or Tylenol):  
  
Medicine  Reasons for Medication  
    
    
    
    
  
  




Dietary Information  
  
Are you currently taking any vitamins, minerals or health food supplements?      
  
If yes, please describe:  
  
Supplement  Amount  How Often  How Long  Reason  
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  YES  NO  
Are you willing to stop your vitamins, minerals or health food supplements while 
participating in a study?  
    
Are you currently following a special diet (i.e., vegetarian, diabetic)?       
If YES, what kind?      
Has this diet been prescribed by your health care provider?      
Are you willing to follow a diet that may vary from your current food intake?      
Have you lost or gained weight in the last 6 months?      
If YES, how much? (Circle one)  GAIN  LOSS  
How do you describe your appetite? (Circle one)  POOR  FAIR  GOOD  
Are you willing and able to eat only the items provided by the research team?      
Do you have problems eating high-fat foods?      
Do you have any food allergies/intolerance?      
   
If so, please explain:  
  
Do you drink caffeinated beverages? (coffee, tea, soda)      
If yes, how many alcoholic beverages do you consume in an average week?      
Can you forego drinking alcoholic beverages for 2 days prior to each trial?      
Do you have a problem eating milk or milk-based products?      
  
If yes, please explain?  
  
Tobacco History  
  





APPENDIX C: MEDICAL HISTORY QUESTIONNAIRE (Cont.) 
 
Did you use tobacco in the past and quit permanently?       
When did you 
quit?  
   
  
Exercise History  
  
  YES  NO  
Do you participate in a regular exercise program?      
  
If yes, please describe the exercise that you usually participate in (e.g., walking, running, 
weightlifting).  
  
Activity  Days/week  Time (min)  No. years  
        
        
        
        
  
For Females Only  
  
  YES  NO  
Are you currently taking estrogen replacement, or hormonal birth control?        
 
If yes, please explain:   
 
 
Are you currently pregnant?      
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Skeletal Muscle Protein Subfractionation 
 
Reagent Notes 
• 1M Sucrose -- maintain the osmolarity of the tissue/ potent oxidant 
• 1M KCl – maintain ion balance 
• 1M EDTA – ion sequestered Ca+, Mg+, non-specific grab everything 
• 0.1 M EGTA/Tris – ion sequestered, specific to Mg+ 
• cOmplete-mini tablet – protease inhibitor for WB 










Soln Storage Amt Reagent 
1M 
Sucrose 
4°C 17.115 g sucrose 
  50 mL ddH2O 
1M 
Tris/HCl 
RT 6.07 g Trizma 
  7.4 pH NaOH 
  50 mL soln ddH2O 
1M KCl 4°C 3.73 g KCl 
  to 50 mL ddH2O 
1M EDTA 4°C 18.61 g EDTA 
  30 mL ddH2O 
  7.4 pH Tris base 
  to 50 mL ddH2O 
0.1 M 
EGTA/Tris 
  2.5364 g EGTA 
  40 mL ddH2O 
  7.4 pH 
(~1.76g) 
Tris base 
  to 60 mL ddH2O 
10% NP-
40 
  1.43 g Tergitol 70% 
  8.57 mL ddH2O 
0.3 M 
NaOH 
RT 3 g NaOH 




RT 86.2 mL 70% PCA 
  1000 mL ddH2O 
70% EtOH RT 294.8 mL 95% EtOH 
  to 400 mL ddH2O 
6M HCl RT 37.14 mL 




Sol Storage Amt Reagent 
RIPA 
-20°C 50 mL ddH2O 
  790 mg Tris base 




  10 mL 10% NP-40 
  0.5 g 
Na 
deoxycholate 





-20°C 670 uL 1M Sucrose 
  500 uL 1M Tris/HCl 
  500 uL 1M KCl 
  170 uL 1M EDTA 





-20°C 2.5 mL 1M Sucrose 
  300 uL 
0.1 
EGTA/Tris 
  100 uL Tris/HCl 
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Supplies 
• Homogenizer (glass if MITO, Teflon if no MITO) 
• 4 mL screw top glass vials 
• Labeled Eppendorf tubes 
 
Homogenization 
• Amt muscle aliquoted dependent on analysis being preformed 
o MITO: 80-100 mg 
o MYO: ~20 mg 
o WB: 50 mg 
1. Weigh/record mass of wet muscle into MYO (COLL if applicable) Eppendorf 
a. Hole in cap if back in -80°C before homogenizing 
2. Cool homogenizer in ice bucket 
a. If MITO/IB1 extraction: glass 
b. If MYO/RIPA: teflon 
3. Transfer MYO muscle into homogenizer 
4. If WB analysis: add enzyme inhibitors to buffers right before homogenizing 
a. 1 cOmplete-mini tablet per 10 mL buffer 
b. 1 PhosStop tablet per 10 mL buffer 
c. Vortex to mix 
5. 10 uL buffer/1 mg wet muscle in homogenizer 
a. If MITO extraction: IB1 
b. If MYO only: RIPA 
6. Pipette homogenate into MYO/COLL Eppendorf 
a. To COLL Eppendorf if collagen analysis 
7. Centrifuge homogenate: 700 x g for 15 min at 4°C 
8. Pellet: MYO and COLL extraction 
a. Can be FREEZED (-80°C) for further processing on a FUTURE date 
b. Hole in cap required! 
9. Supernatant: aliquoting depends on analysis 
a. If MITO: all supernatant into MITO Eppendorf 
i. Follow “MITO Isolation” for further processing SAME DAY 
b. If SARC: 100 uL supernatant minimum 
i. Follow “SARC Isolation” for further processing SAME DAY 
c. If WB only: 
i. BCA: 6 uL 
ii. WB: rest of supernatant 
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MYO Isolation 
1. Wash MYO pellet: 400 uL ddH2O; vortex 
2. Centrifuge: 700 x g, 10 min, 4°C 
3. Discard supernatant 
a. Can freeze -80°C at this point for future processing 
4. Add 1 mL 0.3 M NaOH; vortex 
5. Heat at 37-50°C, 30 min 
a. Setting: low, 5-6 
b. Vortex every 10 min 
6. Centrifuge: 10,000 x g, 5 min, 4°C 
7. Transfer supernatant to MYO 4 mL screw top glass vials 
8. Add 1.0 mL 0.3 M NaOH to MYO Eppendorf; vortex 
9. If samples appear pink: 
a. Heat at 37°C, 10 min 
10. Centrifuge: 10,000 x g, 5 min, 4°C 
11. Transfer supernatant to “old” in 4 mL screw top 
a. Follow “MYO Recovery” for further processing 
12. Pellet = COLLAGEN 
a. Freeze at -80°C for future processing 
 
MYO Recovery 
1. To MYO 4 mL screw top supernatant: Add 1.0mL 1 M PCA 
a. Should see “snow globe” effect 
2. Centrifuge uncapped: 3000 x g, 10 min, 4°C 
a. Accel: max Deaccel: 6 
b. Spinning too fast will break glass 
3. Discard supernatant 
4. Add 500 uL 70% EtOH; do not vortex 
5. Centrifuge: 2000 RPM, 10 min, 4°C 
6. Discard EtOH 
7. Add 1.5 mL 6 M HCl 
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Cation Exchange Purification 
Plasma and Muscle AA quantification/enrichment prior to LC-MS/MS 
 
Supplies: 
1. 1000 mL beaker 
2. Stir bar 
3. pH paper 
4. 5 mL syringes x n+1 
 
Reagents: 
1. Dowex™ 50WX8-200 ion-exchange resin 
2. 4 M NH4OH  
3. 2 M NH4OH 
4. 1 M HCL  
5. 0.1 M HCL 
 
Dowex Slurry Preparation: 
1. Weigh out 200 g of Dowex Resin in a 1000 mL beaker 
2. Add 500 mL of ddH2O 
3. Stir for 5 min on stir plate 
4. Wash with ddH2O 
a. add ddH2O → let resin sink to the bottom → discard water 
5. Keep repeating until solution is neutral (check regularly with pH strips) 
6. Add 500 mL of 4 M NH4OH 
7. Stir for 15 min on stir plate 
8. Let Resin settle to bottom and discard NH4OH 
9. Check pH with strips—should be very basic 
10. Wash with ddH2O 
a. add ddH2O → let resin sink to the bottom → discard water 
11. Keep repeating until solution is neutral (check regularly with pH strips)  
12. Store in fridge with a little layer of 0.1 m HCL on top of it 
**ensures Resin does not dry out 
 
Column Preparation: 
1. Pull out plunger of 5 mL syringe 
2. Add small amount of glass wool to syringe 
a. Compact wool in syringe to 1 mL mark like picture below 
b. Push the wool down firmly with a pen/tweezers/plunger. Even amount between 
syringes, not creeping up on sides. 
 
Column Clean Up: 
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2. Add 1 mL Dowex Resin with 5mL pipette (keep it consistent across all columns) 
3. Add 1.5 mL 2 м NH4OH to elute contaminants 
a. Tally volume added until pH paper blue (basic pH) 
4. Add 2 mL ddH2O until neutral 
a. Tally volume added until pH paper green (neutral pH); usually 6-8 mL 
5. Add 1.5 mL 1 м HCL to charge column. Acidic columns retain samples 
a. Tally volume added until pH paper red (acidic pH); usually ~3 mL  
6. Make test sample: 2 mL 6 M HCl + 1.5 mL ddH2O 
7. Add 1.5 mL ddH2O to sample hydrolysates 
8. Gently add the samples/test to respective columns 
9. Add 1 mL ddH2O to columns until neutral 
a. Tally volume added until all columns neutral (green pH paper) 
b. Usually requires ~6 mL 
c. Note if some samples require more volume to become neutral 
 
Test Column ONLY: Elution 
10. Add 2 M NH4OH to your test column in 500 μL increments until basic 
a. Tally volume added until pH paper blue (basic pH) 
b. If only 500 μL needed, skip to “Sample Columns: Elution” 
11. Subtract 500 μL from volume added to test 
12. Add calculated volume of 2 M NH4OH to sample columns 
 
Sample Columns: Elution 
1. Place newly labeled sample glass vials under sample-containing columns 
2. Add 4 mL 2 м NH4OH to elute all amino acids the column. 
3. Wiggle the samples to fully expel all solution into 4 mL glass vials. 
4. Dry down in Speedvac 
a. Heat time: 2h 
b. Run time: 6h at 45 °C 
c. Vacuum: 1.1 
 
LC-MS/MS Preparation: 
1. Reconstitute in 0.1 м HCL (50 mg/mL sample) and transfer to newly labeled Eppendorfs 
2. Store in Freezer (-80°C)  
3. When submitting for analysis by LC-MS/MS provide only 20 μL of total sample 
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Mixed Plasma Protein Extraction 
Plasma needed: 200 µl 
Supplies: 
1. 1.5 ml Eppendorf tube 
2. 18 G needle 
3. 4 ml screw top vial 
Reagents: 
4. 100% Acetonitrile (ACN) or 2% PCA 
5. 70% Ethanol (EtOH) 
6. 6 M HCL  
Plasma Protein Extraction: 
1. Thaw baseline plasma samples on ice. 
2. Add 500 µl ACN or PCA to Eppendorf. 
3. Add 200 µl of plasma directly to ACN in Eppendorf. 
4. Vortex 
5. Spin at 10,000 RPM for 5 min (4˚C). 
6. Discard supernatant 
7. If sample is hazy: 
a. . (i.e., add 500 µl of ACN or PCA, spin, discard supernatant) 
8. Wash pellet with 500 µl of ddH2O. 
9. Vortex 
10. Spin at 10,000 RPM for 5 min (4˚C). 
11. Discard supernatant. 
12. Wash with 500 µl 70% EtOH and vortex 
13. Spin at 10,000 RPM for 5 min (4˚C). 
14. Remove and discard supernatant. 
15. Poke hole in Eppendorf with needle. 
16. Freeze dry pellet. 
I. Turn on pump 
II. Turn on Freeze-dryer (back button) (3001 mT); wait for vacuum 
III. Put Eppendorf in container and attach to freeze dryer; turn valve 
IV. Clean freeze-dryer after use 
17. Place in 4 ml screw top vial. 
18. Add 1.5 ml 6 M HCL and Hydrolyze overnight at 110˚C. 
19. Purify amino acids over Dowex cation exchange column and convert to NAP derivative for 
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NEP Lab: Plasma Preparation for LC-MS (Total AA, Enrichment, Quantification) 
 
Items needed: 
1. Pure methanol (940uL per sample) 
2. 50uL of sample 
3. 0.1% formic acid in H2O (Keep close tight) (1mL per sample) 
4. LCMS-IS for 10 μL * # samples * 2 (ex. 20 samples = 800 μL) 
5. 2 pair of Epp (1,1; 2,2; 3,3…etc) with number and record file in Drive.  
6. LCMS ready vials labelled with sample codes – HANDWRITTEN; NO PRINTED LABELS. 
 
Procedures  
1. Turn the pump of SpeedVac to be ready when you finish. 
2. Before add the samples, make sure they are thawed and vortexed.  
3. Add 50μL of sample to labelled epp. 
4. Add 940μL of pure methanol to labelled epp.   
5. Vortex for 10 seconds. 
6. Set Centrifuge: 
a. 4°C – (Can use room temp microcentrifuge if needed) 
b. Max Relative Centrifugal Force (RCF) 
c. 10minutes 
d. *** Centrifuge again after pipette if is not clear. 
7. Pipette 700 μL of Supernatant to new Epp. (the rest will be precipitated protein) 
8. Discard Pellet.  
9. Add 10μL of LCMS-IS (vortex the IS before) – (DL-p-Chlorophenylalanine - Prepared with 
1mg to 1mL of 0.1 M HCl) – Important to keep pipetting variability low. Use same pipet and 
same researcher for all samples. 
10. Put in the SpeedVac (Settings): 
a. 45°C. 
b. 2 hours (Heat Time) 
c. 8 hours (Run Time) 
d. Click Auto Run 
1. Check if the samples are wet or not. 
a. If the samples are wet, re-run SpeedVac: 1-2hours (Heat Time) 
– 4 Hours (Run Time), Temp: 45°C. 
11. Re-suspend with 1mL of 0.1% formic acid in H2O. 
12. Vortex for 10 seconds. 






APPENDIX F: PLASMA AMINO ACID EXTRACTION AND QUANTIFICATION 
(Cont.) 
 
b. Max Relative Centrifugal Force (RCF) 
c. 10minutes 
d. *** Centrifuge again after pipette if is not clear. 
14. Remove from centrifuge and transfer 500 µL supernatant to LCMS ready vials. Do not 
vortex! 




APPENDIX G: MUSCLE INTRACELLULAR RECOVERY AND EXTRACTION 
 
Muscle Intracellular Free Pool Extraction Protocol 
 
Tissue needed: 15-20mg 
 
Reagents needed:  
1. 0.6M Perchloric acid (PCA): 25.9mL of 70% stock PCA into 500mL ddH2O 
2. 70% Ethanol (EtOH) 
3. 0,3M NaOH 
4. 1M PCA 
5. 6M HCl 
 
Supplies needed: 
1. Teflon pestle 
2. 1.5mL Eppendorf tube 
3. 2.0mL crimp top vial and cap 
4. 4mL screw top vial 
 
Intracellular Pool Extraction: 
1. Place chipped muscle in 1.5mL Eppendorf tube on ice and add 500uL 0.6M PCA 
2. Homogenize thoroughly with Teflon pestle 
3. Spin at 4500 RPM for 5min at 4°C 
4. Remove supernatant (IC-1st extraction) and place in 2mL Eppendorf tube labelled IC 
5. Add 500uL 0.6M PCA to pellet and vortex 
6. Spin at 4500 RPM for 5min at 4°C 
7. Remove supernatant (IC-2nd extraction) and place in same 2mL Eppendorf tube labelled 
IC 
8. Spin at 4500 RPM for 5min at 4°C 
9. Remove supernatant (IC-3rd extraction) and place in same 2mL Eppendorf tube labelled 
IC 
10. At this point can leave the IC stored at room temp. if going to column the subsequent day 
or freeze at -80°C if going to column at a future date 
11. Freeze protein pellet at -80°C for future processing 
 
 
